YOLFTbeta
Biomotion Sciences Ordinary Shares

Biomotion Sciences Ordinary Shares

SLXN · NASDAQ · Healthcare / Biotechnology

1.98USD-0.68 (-25.56%)

Price History

Full chart

Market Stats

Previous Close2.66
Open2.55
Day Range1.82 – 2.62
52-Week Range0.236 – 42.60
Volume102.62K
Market Cap1.38M
P/E (TTM)0.00
Forward P/E0.00
EPS-19.89
Dividend Yield0.00%
Beta-0.36
50-Day Avg0.9355
200-Day Avg9.45

About

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Ilan Hadar M.B.A.
  • Employees13
  • HeadquartersThe Goldyne Savad Inst. of Gene Therapy, Jerusalem, Israel, 9112001, USA
  • Websitehttps://silexion.com

Leadership

  • Mr. Ilan Hadar M.B.A.Chairman & CEO · b. 1969
  • Ms. Mirit Horenshtein HadarEVP of Finance Affairs, CFO & Secretary · b. 1984
  • Dr. Mitchell Shirvan M.B.A., Ph.D.Chief Scientific & Development Officer · b. 1954

Financials

Income Statement

Currency: USD2012-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---0000
Cost of Revenue-----25.00K14.00K
Gross Profit------25.00K-14.00K
Operating Expense-----12.55M-11.65M
Operating Income--195.86K-943.93K-3.86M-4.68M-12.57M11.63M
EBITDA--195.86K-755.00K-3.32M-5.02M-16.48M-11.88M
Net Income--195.86K-755.22K-3.21M-4.94M-16.44M-11.91M
R&D---3.23M3.71M5.82M7.14M
Interest Expense---85.00K9.00K52.00K13.00K

Balance Sheet

Currency: USD2012-12-312013-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets--129.40K115.41M9.33M5.26M2.86M7.21M
Total Liabilities--299.39K508.92K16.41M17.31M6.85M4.61M
Total Equity---169.99K114.91M-10.66M-15.48M-3.99M2.60M
Cash--51.70K38.94K8.26M4.59M1.19M5.99M
Total Debt----271.00K171.00K4.49M468.00K
Net Debt---51.70K-38.94K-7.99M-4.42M3.30M-5.52M

Cash Flow

Currency: USD2012-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-911.00K-75.00K-1.41M-3.33M-4.53M-8.40M-10.82M
Investing Cash Flow-28.00K---524.00K573.00K-22.00K-14.00K
Financing Cash Flow1.72M126.70K116.40M2.75M522.00K5.10M15.64M
Capital Expenditure3.00K0440.00K12.00K22.00K9.00K
Free Cash Flow--75.00K-1.41M-3.38M-4.54M-8.42M-10.83M
FCF to OCF-100.00%100.00%101.20%100.26%100.26%100.08%

Earnings

Report DateMay 25, 2021Aug 16, 2021Nov 9, 2021Mar 31, 2022May 23, 2022Aug 15, 2022Nov 14, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023May 15, 2024Aug 13, 2024Nov 14, 2024Mar 18, 2025May 13, 2025Aug 7, 2025Nov 12, 2025Dec 31, 2025May 15, 2026Aug 14, 2026Nov 11, 2026
EPS Estimate0.00-------------148.50-147.00--0.21-34.00-11.20-12.90-2.12-
EPS Actual-0.01-0.01-0.02-0.02-0.020.390.020.033.702.01-10.02-0.05-0.03-2740.50-3114.00-0.26-4.32-28.80--8.50-5.17-
Surprise--------------1745.45%-2018.37%--1956.71%15.29%-34.11%-143.87%-
Timing-----------After-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-market-After-hoursPre-market-

Key Statistics & Ratios

Market Cap1.38M
Enterprise Value-43.07K
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book40.02
EPS-19.89
Book Value0.008
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-14.12M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-897.46%
Return on Assets-123.27%
Shares Outstanding5.56M
Shares Float5.56M
Beta-0.36
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 1 analystsTarget 5.00
  • Buy
    1

Ownership Breakdown

Institutions
0.79%
Insiders
27.16%
Retail / Other
72.05%

Top Institutional Holders

  • TWO SIGMA SECURITIES, LLC
    11.66K0.02%
  • A. Montag & Associates Inc
    3.00K0.01%
  • UBS Group AG
    5170.00%
  • Pflug Koory, LLC.
    330.00%
  • JONES FINANCIAL COMPANIES LLLP
    260.00%
  • SBI Securities Co Ltd
    200.00%
  • Citadel Advisors Llc
    00.00%

Stock Splits

  • May 29, 20261:10
  • Jul 29, 20251:15